9999999997-15-012833.txt : 20150827
9999999997-15-012833.hdr.sgml : 20150827
20150827094939
ACCESSION NUMBER: 9999999997-15-012833
CONFORMED SUBMISSION TYPE: CT ORDER
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20150827
DATE AS OF CHANGE: 20150827
20150827
20150827
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CONCERT PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001367920
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: CT ORDER
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36310
FILM NUMBER: 151077454
BUSINESS ADDRESS:
STREET 1: 99 HAYDEN AVENUE
STREET 2: SUITE 500
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-860-0045
MAIL ADDRESS:
STREET 1: 99 HAYDEN AVENUE
STREET 2: SUITE 500
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: CONCERT PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060628
CT ORDER
1
filename1.pdf
begin 644 filename1.pdf
M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S
M=')E86T-96YD;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @(" @(" @#0HR
M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T
M:" V,B]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G (.)@94P C$+ P<#%LP(# @-C$R(#7!E+T]B:E-T;3X^X, IB,@8!HS2&*ZNR.U)WR5::F7.=PG#+ KWTRE9U)4VOC3EF&Q\
MYNACIH/739TE2F_(^F9!4G72V^G4A'];PR]9M,HS:E\HH"31JOQN?N?0]8>Q2+G)
MC[INR(]!*[;1N6P5QKQ4_K;*ZEU>[526V9F>>7JG#^V&!Q1P!=39X4+,\SQP,1CQVO[;&X+S
M[HL[# 6$C($0D=U>%-LH],>^[^*,'V-<5A"$%G7OT+/MU["N;U[HOY:3R>4B
MSQ$ADX#G_]KT2#)]+D(JW2?"?ZO-?4%_$WR>^M^J.TY'N./L/
MW5T6S@'WZ\H;W_KICE5GM=8I!_6$DS]7Z707&>L4A6B?Y2+'2KLLU W6'EJK
MH8[34'.HYO'_I&? !YC5NCL;'?X18 !$B8>^#0IE;F1S=')E86T-96YD;V)J
M#3$T(# @;V)J#3P\+T9I;'1ER$#=<7L6\*;HX"F*YE6B@@%T4%+F2
MMZ!)A5S&T=]W]D+=[!AM95A<+G=FSIPY,]2'FS6%73OXE X^I*D'%-+M@'K@
MXA]>$A=B=T1& :3/ Q=V^)_F\NME8(&=_CV@(W HH2&D4[.3_FH6CD^2Y/34
M(:Y+$VEN%B^#!^M^N4AGMA.0Q)K"VG9"$ENI3:@U3O7NS&R"_6?Z9>!$)([#
M2Y]N9'S*A?2YGDWN5XMT8>/I !W >#D%#.*3R/IC\GF\O#$W,+F[O5VLUXN[
MI78?$S^Z8/PEG.%BWHD"+ @O;5GK$-/6R^F,[08?X5T-1NGMWAC
MZ$+#*#Q#9HPU\S)B^GD&/5_(U,SP ^-)"G=SH(DOZ?>LP#C$4@3O9$HI"?U7
MX?(C:AEX4E:\
M9+"L"6"I'#_RJ0L.3.:_@.^%GBX4)0$]-_GKK8\ZB:T0Z%:0%!K%!2>-NYVA+;TVS[K:,>+4U98NP]ZYC">=
M^HQVOJC;BX
M /8C+[L"<6^;6MIC]XDG!K,?3WS#10NBA@SF=FS5-AE9C3EB\.L(%Y33(^6Z
M,:GK_ Y;U$ !&/ V.P"END=)/Y6N)81;TCXX>DHNBH?$?LI:[:]A^X:UR(WB
M&4D/K!8V![BNKV=="QJS5,V+1LW3A5)Z(1\+ 3I<0OW59R;>K,F$0!AZC];FT7ZT@D=[J#Q/^?>C4#P#
M\52*!ZN57C#BI&[V=:.=SKD$SN )H.E2:""[Y2F3K8E0+]JSA==%"NV>YU%3QL8>F_/YTR)YW"([!(#%O6("^
M<<%6
MKH$1W%NQO/\6RZ.7P4Y!WLOZ%'W>J%>=7A.
ML8Z?3Y(USVKP$HQ03?*";5AI,H6\EVUIR/TB[Q-DG^A[LSV7%XK;O#\O'84^
M+DKE'Q>%/MKV'HX#\?C[3LDO.,H//VN6-TQDS0&G:G2R^%>)_H_%+!W\(\
M7.O("@T*96YDG)E4WI.5&-Z:V,Y9"(_/@H\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C0M8S P-2 W."XQ-#&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O(@H@(" @(" @(" @("!X;6QN"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M
M(&-T;W)D97)V,3PO&UP.D-R96%T941A=&4^,C Q-2TP
M."TR-U0P.3HT-CHU-2TP-#HP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @
M(#QX;7 Z0W)E871O&UP34TZ26YS=&%N8V5)
M1#YU=6ED.C4Q-35F,SDX+3ED8S(M-&$Q,RUA,6)C+3EA83AF-F%C93&UP34TZ26YS=&%N8V5)1#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(#POJ'5!:DZ@?(ZQ"H,P% !_Y6TF
M@QK%M+6(('45A):ZN-@DI8'@*\]G_?TZ=.Y^=UP)"JHJ;59^(0F+Q#AO,KV0
MF]CCW$[L1'O.5:;5*3^JLCAH':LB4BKZ4;O67PWY-^O$A@!W1\MN@D[R))=I
MA_9_I">TJW$D&D/XF!A:O[ /P1%D6:)@%(.?+6[+*&5Z\QRF4@,3 O5'EP92]8
M4F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F( B9&KL4,3 R,;4""=PZ(U0LB
MF($2S]8 60P,C$""Z3^08&0 "# >+4%&PT*96YD